now browsing by category


The Ultimate Smart home | The Best New Smart Home Tech!

The Ultimate Smart home | The Best New Smart Home Tech!

Subscribe ▶
Smarthome Tech Vol 1 ▶
Smartthings Hub ▶
Harmony Hub ▶
Motion Sensor (for Smartthings) ▶
USB C Outlets ▶
My Smarthome STUFF #kit ▶
Harmony Hub Review ▶
What Stuff Do I Use? (Kit) ▶
What Camera Gear Do I use? (B&H) ▶

Music Created By @Iamrevolution //
Rap By ▶ James_C_L – Intro & KTTN Say It Again.

VP Global Digital Strategy & Transformation

VP Global Digital Strategy & Transformation

In partnership with the SVP, Global Digital Strategy and Transformation, the Chief Digital Officer and other stakeholders, you will build and refine the…

New York, NY

From MetLife 5 days ago

Machine Learning Engineer

Machine Learning Engineer

Natural Language Processing, text understanding, classification, pattern recognition, recommendation systems, targeting systems, ranking systems or similar….

San Francisco, CA

From Mercari 24 days ago

Why there’s no model for the perfect healthcare system

Why there’s no model for the perfect healthcare system

Sherry Glied, Dean of New York University’s Robert F Wagner Graduate School of Public Service, and former assistant secretary for planning and evaluation at the Department of Health and Human Services, explains why there is no perfect healthcare system.


Follow BI Video on Twitter:
Follow BI on Facebook:
Read more:


Business Insider is the fastest growing business news site in the US. Our mission: to tell you all you need to know about the big world around you. The BI Video team focuses on technology, strategy and science with an emphasis on unique storytelling and data that appeals to the next generation of leaders – the digital generation.

Customer Service Specialist (ICS)

Customer Service Specialist (ICS)

To the coffee shop down the street, we are leading the transformation in payments through chip-enabled cards, mobile wallets, eCommerce, and payment solutions…

Durango, CO

From Vantiv 3 days ago

Biomarker Technology Platforms For Cancer Diagnoses And Therapies — Aarkstore Enterprise

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. The purpose of this Publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctors offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.

Table of Contents :
1. Overview 12
1.1 Statement of Report 12
1.2 About This Report 12
1.3 Scope of the Report 12
1.4 Objectives 13
1.5 Methodology 14
1.6 Executive Summary 15

2. Introduction to Cancer Biology and the Diagnostic Industry 17
2.1 Biomarkers 17
2.1.1 The Biomarker Market Drivers 17 The Sector 17 The Critical Path Opportunities 17 The Capital Markets 17
2.2 Cancer Detection and Treatment with Biomarkers 18
2.2.1 The Problem 19
2.3 Cancer: The Disease 21
2.3.1 Metastasis 21
2.3.2 Demographics and Statistics of Cancer 22
2.4 Drivers of the Biotech and Diagnostics Industry 28
2.4.1 Venture Funding of Biotech Sector 29
2.4.2 Technological Innovation 30
2.4.3 Government Funding 30
2.4.4 Pharmaceutical Development and Bioanalytical Services 30
2.4.5 The War on Cancer 32
2.4.6 Current Oncology Drug Development 32
2.5 Outlook for Tumor Markers 32
2.6 Focus on Proteomics 35
2.6.1 Scientific Background 35
2.6.2 The Relationship between Proteins and Diseases 35
2.6.3 Limitations of Existing Diagnostic Approaches 36
2.6.4 Addressing the Heterogeneity of Cancer 36
2.6.5 Validation of Biomarkers Through Proper Study Design 37
2.6.6 Exploiting the Power of Mass Spectrometry to Improve Assay Specificity 37
2.6.7 Creating and Maintaining a Multi-Disease Product Pipeline 39
2.6.8 Partnerships for Developing Proteomic Biomarkers 39
2.7 Epigenic Markers for Cancer 40
2.8 Molecular Diagnostics Testing for Cancer 41
2.9 Market Opportunities 41
2.9.1 Industry Overview 42
2.9.2 Medical Indications and Medically Useful Information 44
2.9.3 Research Market 45
2.9.4 Competition 46
2.9.5 Diagnostic Services 46
2.9.6 Clinical Image Analysis 46
2.9.7 Research Imaging Market 46
2.9.8 Genomic Disease Management and In Vitro Diagnostic Multivariate Index Assays (IVDMIA) 46
2.9.9 Predictive Expression Profiles 47

3. Market Analysis of the Cancer Biomarkers Space 48
3.1 Scope of this Chapter 48
3.2 The Overall Market Opportunity and Segmentation of the Total Cancer Biomarkers Marketplace 48
3.3 Potential Cancer Biomarker Commercial Applications 51
3.3.1 Market for Routine Tumor Markers 52
3.3.2 Market for Genomic Cancer Biomarkers 57
3.3.3 Market Size and Forecasts for Companion Diagnostic Tests for Cancer Therapeutics 59
3.3.4 SWOT Analysis of the Major Cancer Biomarker Market Segments 61 Traditional Serum Cancer Biomarkers 61 Proteomic Cancer Biomarkers 62 Companion Diagnostic Cancer Biomarkers 63
3.4 Cancer Biomarker Market Estimates by Tissue of Origin 64
3.4.1 Colorectal 64
3.4.2 Prostate 65
3.4.3 Lung 65
3.4.4 Breast 65
3.4.5 Ovarian 66
3.5 Challenges Facing Cancer Biomarker Developers 66
3.6 Unmet Product Needs in the Cancer Biomarkers Space 68
3.7 Competitive Landscape of the Cancer Biomarkers Marketplace 70

4. Major Clinical Applications of Cancer Biomarkers 73
4.1 Launched Products and Pipeline 73
4.2 CYP2C9 Pharmacogenetics and Role in Personalized Medicine 75
4.3 Personalized Breast Cancer Therapy 75
4.4 Personalized NSCLC Therapy 76
4.5 AmpliChip-based Personalized Medicine 76

5. Breast Cancer 77
5.1 Overview of Breast Cancer Disease 77
5.2 BRCA1 and BRCA2 Genes 78
5.2.1 Types of Genetic Testing Available for Breast Cancer 80 DNA Sequencing 80 Multi-Site Analysis 81 Single-Site Analysis 81
5.2.2 BRCA Test Results 81 What Does a Positive BRCA1 or BRCA2 Test Result Mean? 81 What Does a Negative BRCA1 or BRCA2 Test Result Mean? 81 What Does an Ambiguous BRCA1 or BRCA2 Test Result Mean? 82 What are the Options for a Person Who Tests Positive? 82
5.2.3 What are Some of the Benefits of Genetic Testing for Breast Cancer Risk? 83
5.2.4 What Are Some of the Risks of Genetic Testing for Breast and Ovarian Cancer Risk? 83
5.3 Estrogen Receptors and Breast Cancer 83
5.3.1 Expression and Prognostic Value of ER 83
5.3.2 Progesterone Receptors and Breast Cancer 84
5.3.3 ER and PR Predict Response to Endocrine Therapy 84
5.4 HER2 Gene and Protein 85
5.4.1 HER2 Tests 85 IHC Test 85 FISH Test 86 Questions About Testing 88 HER2 Tumor Status 89
5.5 Herceptin Treatment 89
5.6 Tumor Assays for Adjuvant Chemotherapy 91
5.7 Use of Genomics to Understand Breast Cancer 92
5.8 Genetic Analysis Solution 93
5.8.1 The Use of Proteomics in Breast Cancer 94
5.8.2 Tissue Microarrays 95
5.8.3 Protein Microarrays 97
5.9 Gene Expression Microarrays and Recurrence Prediction 98
5.9.1 Oncotype DX 99
5.9.2 Oncotype DX for Breast Cancer 100
5.9.3 Risk Assessment 100
5.9.4 Use of Chemotherapy 100
5.9.5 Utility of the Oncotype Test 100
5.9.6 Clinical Development and Validation of Oncotype DX 101 Clinical Development of the Oncotype DX Recurrence Score 101 Clinical Validation of Prediction of Recurrence and Survival in N, ER+ Patients Treated with Tamoxifen 101 Oncotype DX Predicts the Likelihood of Recurrence 102 Oncotype DX Predicts the Likelihood of Breast Cancer Survival in a Community Hospital Setting 102 Oncotype DX Predicts both Prognosis and Tamoxifen Benefit 103
5.10 Economic Benefits of Oncotype DX 103
5.11 Increased Clinical Utility of Oncotype DX 104
5.12 Second Generation Oncotype DX 105
5.12.1 Recurrence and Benefit Test for N, ER Breast Cancer 105
5.12.2 Taxane Benefit Test 105
5.13 MammaPrint 105
5.14 Rotterdam Signature 76-Panel 106
5.15 Summary of Microarray Technologies 106
5.16 Mass Spectrometry-based Approaches 107
5.16.1 Gel-based Approaches 107
5.16.2 Non-Gel-based Approaches 108 SELDI-TOF MS 108 SELDI and Prognosis 109 SELDI and Treatment Monitoring 110
5.16.3 Limitations of Mass Spectroscopy 110
5.17 Outlook 111
5.18 Future Perspectives 113
5.19 Breast Cancer Program (NMP66) 114
5.20 Myriad Genetics 114
5.21 Veridex GeneSearch Breast Lymph Node 115
5.22 OncoVue Cancer Risk Test 115
5.23 Research Biomarkers for Breast Cancer 115
5.24 Protein Biomarkers for Breast Cancer Prevention 116
5.25 Biomarker Prognosis of Breast Cancer Treated with Doxorubicin 116

6. Ovarian Cancer 117
6.1 Serum Markers 119
6.2 Biomarkers 120
6.2.1 Strategies for Discovering New Cancer Biomarkers 121
6.3 Serum Protein Biomarkers for Ovarian Cancer 121
6.3.1 Clinical Proteomics 122
6.4 Ovarian Cancer Triage Testing 123
6.4.1 Vermillions Ovarian Cancer Triage Diagnostic Program 124

7. Prostate Cancer 126
7.1 Overview 126
7.1.1 Prevalence 126
7.1.2 Prostate Cancer Progression and Recurrence Test 126
7.1.3 Current Market Size 126
7.2 Genes Involved in Prostate Cancer 127
7.3 Androgen Independence 128
7.4 Gene Markers in Prostate Cancer 129
7.5 Microarray Gene Identification of Prostate Biomarkers 129
7.6 GEArray DNA Microarrays 131
7.7 Vermillions Cancer Diagnostic Program 132
7.8 Hepsin 132
7.9 Matritechs Prostate Cancer Program (NMP48) 132
7.10 Gen-Probes PCA3 Assay 133
7.11 Early Prostate Cancer Antigen-2 (EPCA-2) 133
7.12 Mass Spectrometry 134
7.13 Summary 136

8. Bladder Cancer 137
8.1 Overview 137
8.1.1 Prevalence 137
8.1.2 Progression and Recurrence 137
8.1.3 Bladder Cancer Risk Factors 137
8.1.4 Bladder Cancer Symptoms 137
8.2 Bladder Cancer Tests 137
8.3 UroVysion Bladder Cancer Kit 138
8.4 Ikoniscope Robotic Digital Microscopy Platform 139
8.4.1 The CellOptics Platform 139
8.4.2 Cell Staining and Genetic Characterization 139
8.4.3 Ikoniscope/IkoniLAN Automated Microscopy 139
8.5 Nuclear Matrix Protein Markers 140
8.6 ImmunoCyt/uCyt+ 142

For more information, please visit :

Contact :Sanaa

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email :

Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

Distribution Agreements

Distribution Agreements

A distribution agreement is an agreement between two parties whereby one party (the supplier) agrees to supply products to the other (the distributor), which the distributor will distribute. It is very common for distribution rights to be granted in relation to a particular territory or market.

Agents, Representatives and Distributor Agreements

An agent is a company or individual who represents another company (the ‘principal’) and who usually receives commission on sales that the agent arranges. An agent for a manufacturer, for example, will find customers for the manufacturer’s goods, the manufacturer will sell directly to the customer and the agent will be paid a commission by the manufacturer.
Sometimes a company will enter into an agreement with a “representative” whose role may be that of an agent or it may be confined to a particular task – e.g. informing the company of opportunities for tendering in a particular country. In this situation, a representation agreement may be required.
A distributor, on the other hand, is someone who buys goods from a manufacturer or supplier and then sells the goods on to its customers, either retailers or end-users. For this situation, a distributor agreement would be required.

Purpose of Distribution Agreement

A company usually enters into a Distribution Agreement to outsource the distribution process and concentrate on the manufacture of the item. There are advantages and disadvantages of outsourcing your distribution

Advantages and Disadvantages of Outsourcing Distribution

If you outsource your distribution the distributor is responsible for warehousing and transporting your goods. They may know more about the local customs and legal issues if you are distributing your product overseas. They will be responsible for any overseas currency risk, for marketing the product, and for carrying the credit risk of the products purchasers.

The disadvantages are that the distributor will want discounts and preferential terms. It is possible to lose control of the marketing and pricing of your product, and distributors might want long terms of exclusivity. However, the benefits discussed in the previous paragraph do show why you might want to enter into a Distribution Agreement with another company.

They will bear the brunt of the issues for expanding into foreign markets as well as promoting your products. With the Distribution Agreement you can set forth terms that both parties agree to covering yourself for product control and pricing. The agreement should cover specific information regarding the contract you have with the distributor
Categories of Distribution Agreement

Distribution agreements may be categorised as either exclusive or non-exclusive. In an exclusive distribution agreement, the supplier will grant to the distributor exclusivity over a particular territory and/or product line and/or sales channel. The usual quid pro quo for exclusivity will be some kind of performance obligations.
Geographical limits of Distribution

Any Distribution Agreement should cover the geographical limits, where you are allowed to sell your product direct, if there will be other distributors, and what the distributor will be paying for your product. If there are any bonuses they should also be mentioned. The agreement should clearly state how long the Distribution Agreement will be in effect and whether it can be terminated early by either party.

Terms and Conditions and Common Issues

Distribution agreements often incorporate terms and conditions of supply and sell, sometimes in the body of the agreement and sometimes as a schedule or annex to the agreement. These should cover all the nitty-gritty concerning supplies and sells, including the delivery of goods, the transfer of risk in and title to the goods, inspection requirements, returns, and so on.
Distribution agreements can fall foul of competition law, and some care should therefore be taken with their drafting.
Common issues to consider when drafting a distribution agreement are:

the territorial or other scope of the agreement;
non-exclusivity or exclusivity (taking into account competition law);
non-compete obligations (taking into account competition law);
minimum performance obligations;
reporting obligations;
marketing rights;
trade mark licensing;
the applicable terms and conditions of sale;
the circumstances in which the agreement may be terminated; and
the consequences of termination.

Informal understandings often lead to misunderstanding. The process of creating and negotiating a contract helps to ensure that the parties really do agree upon the terms of the deal. Equally important, where something does go wrong, a written agreement will usually help.

Minimum Target Obligations

The manufacturer will impose some form of minimum target obligation on the distributor to ensure that the relevant market is fully exploited. The minimum target obligation can be either for a minimum level of sales by the distributor to its customers, or for a minimum level of purchases by the distributor from the manufacturer. It has to be provided in the agreement as to what is to happen if the distributor fails to comply with the minimum targets.

Can a Distributor pay after Selling Product?

Usually the distributor is required to purchase the products from the supplier before selling them on. However, arrangements can be made in an agreement whereby the parties agree that the distributor will pay for the products after it has resold them

Binding Effect of Distribution Agreement

Once the agreement has been signed by both parties it is a legally binding contract. Changes, unless agreed upon by both parties, cannot be made and will usually require a new Distribution Agreement to be created and signed. The agreement is based on the laws of England and Wales, but for distribution overseas you may need to make changes regarding jurisdiction depending on where the distribution will occur.

The termination of the agreement and the consequences of termination may be handled in a number of ways. One matter that will require particular care is disposal of stock on termination.

Net Lawman’s Distribution Agreements
All of our distribution agreements include optional terms and conditions. Our agreement clearly defines the responsibilities of both the Principal and the Distributor and so helps to ensure that both parties adhere to the terms of the agreement. Our template outlines the standard Distribution Agreement and can be customised to suit your needs.

Our distribution agreements are designed for use in relation to territorially-based distributorships within the EU irrespective of the location of the supplier.
We provide accurate, legal and secure forms. All of our forms have drafted by expert team of Solicitors and Barrister who are up-to-date with current legislation. Our forms can be downloaded and accessed immediately, and are backed by a 100% money back guarantee – if you are dissatisfied, in any way, you get your money back.

Net Lawman is an English UK based company providing legal services. Net Lawman provides quality distribution agreement for the distributors. Distributor agreement is a legal contract between the distributor and the supplier.
Also visit our Joint venture agreement and stock transfer form pages.

Summer Business Strategist

Summer Business Strategist

From Insight to Action, we define business models — profit, process, channel, brand and partnership strategies — and create new physical and digital products,…

IA Collaborative
Chicago, IL 60603

From IA Collaborative 22 days ago

htc One M8 review, mid 2017

htc One M8 review, mid 2017

The review unit is brand new, running a custom sTeam rom based on stock Marshmallow with Sense 8 and Dolby Atmos plugin.

The first 4 minutes talk about why I chose this device again, the actual review starts at 4:00

Wifi Smart Plug Mini, GMYLE Smart Home Power Control Socket, Remote Control Your Household Equipment from Everywhere, No Hub Required, Works with Amazon Alexa, Echo Dot & Google Home (2 Packs)

Wifi Smart Plug Mini, GMYLE Smart Home Power Control Socket, Remote Control Your Household Equipment from Everywhere, No Hub Required, Works with Amazon Alexa, Echo Dot & Google Home (2 Packs)

Product Description
Model: WS-1
Type of Plugs: Plug Type B
Power Rating: 100-125VAC 10A
AC Frequency: 50/60Hz
Operation temperature: -10°C ~ +40 °C
WiFi Standard: Wi-Fi 2.4GHz b/g/n
App Support: Android 4.1 and IOS 8.0 or higher

Price: $30.98

  • Plug in a GMYLE Wi-Fi smart plug, control your appliances through an App  on your smartphone and tablet anywhere. With Wifi control, no hub or subscription needed.
  • Works with Amazon Alexa and Google Home, turns on or off appliances by voice control .
  • Easy to install. All you need to do is setting up your Smart Plug with wifi network, plug in and register the appliances. Compatible with 2.4 G wireless network. (Not support 5G wireless network.)
  • Countdown function allows you to turn on or off appliance automatically, preventing power waste and over-charging .
  • Schedule automatically. Set up worry-free schedule by using  timer function. Turn on/off your devices based on specific time you set; Never come back to a dark house. Schedule the fan to turn on before you arrive. Sync lights and devices to pre-set times automatically.